Grifols SA
SWB:OZTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Grifols SA
SWB:OZTA
|
ES |
|
S
|
Strata Critical Medical Inc
NASDAQ:SRTA
|
US |
|
S
|
Sumitomo Pharma Co Ltd
XMUN:DPM
|
JP |
|
O
|
Obzen Inc
KOSDAQ:417860
|
KR |
|
C
|
Compass Inc
F:91D
|
US |
Intrinsic Value
Is OZTA undervalued or overvalued?
See the intrinsic value estimate for 
Grifols SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
OZTA looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with OZTA’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Grifols Does
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.
- Headquarters
- Spain ES
- Employees
- 25 000
- IPO date
- May 17, 2006
Grifols has no economic moat
Grifols SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Grifols SA
Earnings Waterfall
Grifols SA
The intrinsic value for Grifols SA (OZTA) under the Base Case is hidden EUR.
Compared with the current market price of 10.025 EUR, the stock appears hidden.